{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T05:41:52Z","timestamp":1781934112981,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Health and Health Innovation Program of Jilin Province under Grant","award":["2018J043"],"award-info":[{"award-number":["2018J043"]}]},{"name":"The Youth Development Foundation of the First Hospital of Jilin University under Grant","award":["JDYY102019005"],"award-info":[{"award-number":["JDYY102019005"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Eszopiclone, sold under the brand name Lunesta, is a new type of non-benzodiazepine hypnotic. Eszopiclone is a zopiclone dextrorotation, which is classified as a cyclopyrrolone. It functions by binding gamma-aminobutyric acid (GABA) receptors. Compared with benzodiazepines hypnotics, eszopiclone has higher selectivity for certain subunits of the GABA(A) receptor. So far, there are no reports about the elevation of serum enzymes or severe liver injury caused by eszopiclone. Here, we present a case report of acute liver injury following eszopiclone treatment in a patient with chronic hepatitis B virus (HBV).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient was a 53-year-old female with a 36-year history of positive HBV markers. Due to poor sleep, the patient took trazodone hydrochloride orally for 1 year. After hospital admission for positive hepatitis B pathogenic markers, abdominal distension, fatigue, and aggravation, she was treated with eszopiclone under the guidance of the mental health department.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Her transaminase levels increased abnormally after eszopiclone treatment and rapidly decreased after drug withdrawal. This was determined to be an acute liver injury event. liver-protecting treatment was maintained. Considering the patient's anxiety and depression, the patient's family members refused a liver biopsy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Transaminase levels decreased rapidly within one week, and the patient continued to take trazodone hydrochloride after discharge. No adverse events occurred in the follow-up period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Sleep disorders are more common in patients with chronic diseases, especially patients with chronic liver disease. Recently, it has become common for patients with hepatitis B and C to use antidepressants along with antiviral treatment. Patients with chronic hepatitis B or C may have a threefold risk of liver dysfunction after receiving antituberculosis treatment.\n                                    <jats:sup>[1,2]<\/jats:sup>\n                                  A proinflammatory environment induced by actively replicating the hepatitis virus may alter the detoxication process and increase drug toxicity.\n                                    <jats:sup>[3]<\/jats:sup>\n                                  At this time, the safety of other drugs should be reevaluated. Although hepatitis and liver injury are listed as rare adverse reactions of eszopiclone, this case is the first to report the eszopiclone-involved acute liver injury.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026243","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:34:19Z","timestamp":1624455259000},"page":"e26243","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Case report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease"],"prefix":"10.1097","volume":"100","author":[{"given":"Tong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijie","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"R1-20250504","first-page":"616","article-title":"Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment","volume":"14","author":"Chien","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","article-title":"Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection","volume":"31","author":"Wong","year":"2000","journal-title":"Hepatology"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0168-8278(99)80325-0","article-title":"Antecedent liver disease and drug toxicity","volume":"31","author":"Schenker","year":"1999","journal-title":"J Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/sleep\/33.2.225","article-title":"A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2\u200amg on sleep\/wake function in older adults with primary and comorbid insomnia","volume":"33","author":"Ancoli-Israel","year":"2010","journal-title":"Sleep"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.1840220320","article-title":"Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions","volume":"22","author":"Banks","year":"1995","journal-title":"Hepatology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","article-title":"Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic","volume":"128","author":"Fountain","year":"2005","journal-title":"Chest"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.21324","article-title":"Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain","volume":"44","author":"Lucena","year":"2006","journal-title":"Hepatology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.amjmed.2015.10.029","article-title":"Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status","volume":"129","author":"Lo Re","year":"2016","journal-title":"Am J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"06","DOI":"10.1016\/j.sleep.2019.03.016","article-title":"Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"62","author":"Liang","year":"2019","journal-title":"Sleep Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/liv.13931","article-title":"The diagnosis and management of idiosyncratic drug-induced liver injury","volume":"39","author":"Hassan","year":"2019","journal-title":"Liver Int"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0269216318807051","article-title":"Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis","volume":"33","author":"Peng","year":"2019","journal-title":"Palliat Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/NSS.S186665","article-title":"Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges","volume":"10","author":"Bruyneel","year":"2018","journal-title":"Nat Sci Sleep"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/ppc.12138","article-title":"Insomnia in adults with chronic hepatitis B, liver failure, and cirrhosis: a case-control study","volume":"53","author":"Guo","year":"2017","journal-title":"Perspect Psychiatr Care"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.genhosppsych.2011.11.012","article-title":"Psychological comorbidities in Chinese patients with acute-on-chronic liver failure","volume":"34","author":"Duan","year":"2012","journal-title":"Gen Hosp Psychiatry"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1572-0241.2000.t01-1-01780.x","article-title":"Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity","volume":"95","author":"Fernandes","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000450878","article-title":"Acute liver failure due to trazodone and diazepam","volume":"24","author":"Carvalhana","year":"2017","journal-title":"GE Port J Gastroenterol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1055\/s-0042-109536","article-title":"Evaluating the role of drug metabolism and reactive intermediates in trazodone-induced cytotoxicity toward freshly-isolated rat hepatocytes","volume":"66","author":"Najibi","year":"2016","journal-title":"Drug Res (Stuttg)"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cbi.2005.03.036","article-title":"Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4","volume":"155","author":"Kalgutkar","year":"2005","journal-title":"Chem Biol Interact"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0006-3223(99)00176-6","article-title":"In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors","volume":"47","author":"Zalma","year":"2000","journal-title":"Biol Psychiatry"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/NSS.S130505","article-title":"Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients","volume":"9","author":"Buxton","year":"2017","journal-title":"Nat Sci Sleep"},{"key":"R24-20250504","first-page":"2703","article-title":"Effects of chronic HBV infection on human hepatic cytochrome P450 3A4","volume":"86","author":"Li","year":"2006","journal-title":"Zhonghua Yi Xue Za Zhi"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:04:54Z","timestamp":1746338694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":24,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026243","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"2021-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}